RGLS Regulus Therapeutics Inc.

1.26
0  0%
Previous Close 1.26
Open 1.26
Price To Book -4.34
Market Cap 26,165,491
Shares 20,766,263
Volume 28,582
Short Ratio
Av. Daily Volume 193,256

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 enrollment has been paused due to financial conditions - noted July 5, 2018.
RG-012 - HERA
Alport Syndrome
Phase 1 trial has been paused due to unexpected observations in mouse toxicity trial.
RGLS4326
Autosomal dominant polycystic kidney disease (ADPKD)

Latest News

  1. Regulus Announces New Additions to Board of Directors
  2. Regulus: 1Q Earnings Snapshot
  3. Regulus Therapeutics Reports First Quarter 2019 Financial Results and Recent Updates
  4. Regulus Therapeutics Announces Closing of First Tranche of $41.8 Million Private Placement of Equity
  5. Regulus Therapeutics Announces Restructuring of Term Loan
  6. Regulus Therapeutics Announces Private Placement of Equity
  7. Will Regulus (RGLS) Report Negative Q1 Earnings? What You Should Know
  8. Regulus to Present Preclinical Efficacy Data Highlighting Potential of Novel Treatment for Nonalcoholic Steatohepatitis at The International Liver Congress™ 2019
  9. Four Healthcare Stocks Getting a Boost on Thursday
  10. Regulus Reports Fourth Quarter and Year-End 2018 Financial Results and Recent Updates
  11. Regulus Announces Transition of Research Leadership
  12. Regulus Announces Clinical Candidate Nomination for the Treatment of Glioblastoma Multiforme
  13. Regulus Announces Preliminary Results of Planned Interim Data Analysis of RGLS4326 in New Mouse Chronic Toxicity Study
  14. Need To Know: Regulus Therapeutics Inc. (NASDAQ:RGLS) Insiders Have Been Buying Shares
  15. Research Report Identifies Advanced Energy Industries, Altair Engineering, Rambus, Regulus Therapeutics, NN, and Halcon Resources with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
  16. Regulus Presents Preclinical Survival Data Highlighting Potential of Novel Treatment for Glioblastoma Multiforme
  17. Regulus (RGLS) Reports Q3 Loss, Lags Revenue Estimates
  18. Regulus Reports Third Quarter 2018 Financial Results and Recent Updates